{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-22-000037","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.681770+00:00","generated_at":"2026-06-25T19:14:55.798510+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval","bullets":["Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.","Cash balance $389.1M as of March 31, 2022; runway projected through mid-2024.","Partner BMS received U.S. FDA approval for mavacamten in obstructive HCM in April 2022.","Partner Tarsus reported positive Phase 3 Saturn-2 data for TP-03 in Demodex blepharitis; NDA planned H2 2022.","Pfizer agreed to acquire development partner ReViral (sisunatovir); LianBio expects to start three Phase 3 trials in China by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-22-000037","json":"https://secwatch.observer/filing/0001831283-22-000037.json","markdown":"https://secwatch.observer/filing/0001831283-22-000037.md","text":"https://secwatch.observer/filing/0001831283-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/0001831283-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/lian-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:14:55.798510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}